DE60119896D1 - Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit - Google Patents

Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit

Info

Publication number
DE60119896D1
DE60119896D1 DE60119896T DE60119896T DE60119896D1 DE 60119896 D1 DE60119896 D1 DE 60119896D1 DE 60119896 T DE60119896 T DE 60119896T DE 60119896 T DE60119896 T DE 60119896T DE 60119896 D1 DE60119896 D1 DE 60119896D1
Authority
DE
Germany
Prior art keywords
pramipexol
tobacco
treatment
nicotine dependence
nicotine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Revoked
Application number
DE60119896T
Other languages
English (en)
Other versions
DE60119896T2 (de
Inventor
C Marshall
H Wong
F Vonvoigtlander
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co LLC
Original Assignee
Pharmacia and Upjohn Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22676121&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60119896(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia and Upjohn Co LLC filed Critical Pharmacia and Upjohn Co LLC
Publication of DE60119896D1 publication Critical patent/DE60119896D1/de
Application granted granted Critical
Publication of DE60119896T2 publication Critical patent/DE60119896T2/de
Anticipated expiration legal-status Critical
Revoked legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60119896T 2000-02-23 2001-02-14 Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit Revoked DE60119896T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18424200P 2000-02-23 2000-02-23
US184242P 2000-02-23
PCT/US2001/001232 WO2001062249A1 (en) 2000-02-23 2001-02-14 Use of pramipexole for the treatment of addictive disorders

Publications (2)

Publication Number Publication Date
DE60119896D1 true DE60119896D1 (de) 2006-06-29
DE60119896T2 DE60119896T2 (de) 2006-11-09

Family

ID=22676121

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60119896T Revoked DE60119896T2 (de) 2000-02-23 2001-02-14 Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit

Country Status (24)

Country Link
US (1) US6410579B2 (de)
EP (1) EP1257271B1 (de)
JP (1) JP2003523387A (de)
KR (1) KR20030016230A (de)
CN (1) CN1396826A (de)
AR (1) AR027945A1 (de)
AT (1) ATE326967T1 (de)
AU (1) AU781358B2 (de)
BR (1) BR0107983A (de)
CA (1) CA2397874A1 (de)
CO (1) CO5261586A1 (de)
DE (1) DE60119896T2 (de)
DK (1) DK1257271T3 (de)
ES (1) ES2263586T3 (de)
HK (1) HK1053058A1 (de)
MX (1) MXPA02008184A (de)
MY (1) MY127739A (de)
NZ (1) NZ520974A (de)
PE (1) PE20011074A1 (de)
PT (1) PT1257271E (de)
SI (1) SI1257271T1 (de)
TW (1) TWI250016B (de)
WO (1) WO2001062249A1 (de)
ZA (1) ZA200206119B (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
EP2305252A1 (de) 2001-12-11 2011-04-06 University Of Virginia Patent Foundation Verwendung von Pramipexol zur Behandlung amyotropher Lateralsklerose
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
MY142204A (en) * 2002-07-25 2010-10-29 Pharmacia Corp Pramipexole once-daily dosage form
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
MX2007001850A (es) * 2004-08-13 2007-03-28 Boehringer Ingelheim Int Formulacion de pildora de liberacion prolongada que contiene pramipexol o una sal farmaceuticamente aceptable del mismo, metodo para fabricarlo y uso del mismo.
EP1781260B2 (de) * 2004-08-13 2014-04-02 Boehringer Ingelheim International GmbH Tablettenformulierung mit verlängerter freisetzung enthaltend pramipexol oder ein pharmazeutisch annehmbares salz, die herstellungsmethode und die verwendung der tabletten
US20070134169A1 (en) * 2005-12-11 2007-06-14 Rabinoff Michael D Methods for smoking cessation or alcohol cessation or other addiction cessation
US20090041844A1 (en) * 2006-02-10 2009-02-12 Boehringer Ingelheim International Gmbh Modified Release Formulation
WO2007090883A1 (en) * 2006-02-10 2007-08-16 Boehringer Ingelheim International Gmbh Extended release formulation
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CA2652251A1 (en) 2006-05-16 2007-11-29 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods for using the same
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
WO2008113056A2 (en) 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
ATE513830T1 (de) * 2007-09-21 2011-07-15 Sanofi Aventis Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US20110190356A1 (en) 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
DE102012108398B4 (de) 2012-09-10 2014-05-22 Schott Ag Kochfeld, Blende, Geräteeinhausung sowie Kamin- oder Ofensichtscheibe mit einem Hologramm und Verfahren zu dessen bzw. deren Herstellung, sowie Verwendung eines Substrats, auf welchem ein Phasenhologramm aufgebracht ist
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
CN105764507B (zh) 2013-07-12 2019-07-19 诺普生物科学有限责任公司 治疗升高的嗜酸性粒细胞和/或嗜碱性粒细胞的水平
ES2813674T3 (es) 2013-08-13 2021-03-24 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de trastornos de células plasmáticas y trastornos prolinfocíticos de células b
ES2871556T3 (es) 2013-08-13 2021-10-29 Knopp Biosciences Llc Composiciones y métodos para el tratamiento de la urticaria crónica

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE45735T1 (de) 1984-12-22 1989-09-15 Thomae Gmbh Dr K Tetrahydro-benzthiazole, deren herstellung und deren verwendung als zwischenprodukte oder als arnzneimittel.
DE3843227A1 (de) 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
DE3930282A1 (de) 1989-09-11 1991-03-21 Boehringer Ingelheim Kg Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
DE3933738A1 (de) 1989-10-10 1991-04-11 Boehringer Ingelheim Kg Neue verwendung von 2-aminothiazol-derivaten (tsh)
DE3937271A1 (de) 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
DE4241013A1 (de) 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
US5650420A (en) 1994-12-15 1997-07-22 Pharmacia & Upjohn Company Pramipexole as a neuroprotective agent
US6001861A (en) 1998-01-16 1999-12-14 Pharmacia & Upjohn Company Use of pramipexole in the treatment of restless legs syndrome
CA2384840A1 (en) 1999-09-30 2001-04-05 The General Hospital Corporation Use of pramipexole as a treatment for cocaine craving

Also Published As

Publication number Publication date
ZA200206119B (en) 2003-10-31
MY127739A (en) 2006-12-29
BR0107983A (pt) 2003-01-28
DK1257271T3 (da) 2006-08-21
AU3445401A (en) 2001-09-03
AU781358B2 (en) 2005-05-19
HK1053058A1 (zh) 2003-10-10
PE20011074A1 (es) 2001-10-04
EP1257271A1 (de) 2002-11-20
US6410579B2 (en) 2002-06-25
ES2263586T3 (es) 2006-12-16
AR027945A1 (es) 2003-04-16
WO2001062249A1 (en) 2001-08-30
EP1257271B1 (de) 2006-05-24
ATE326967T1 (de) 2006-06-15
KR20030016230A (ko) 2003-02-26
US20010041727A1 (en) 2001-11-15
DE60119896T2 (de) 2006-11-09
CA2397874A1 (en) 2001-08-30
TWI250016B (en) 2006-03-01
CN1396826A (zh) 2003-02-12
CO5261586A1 (es) 2003-03-31
SI1257271T1 (sl) 2006-10-31
PT1257271E (pt) 2006-09-29
MXPA02008184A (es) 2002-11-29
NZ520974A (en) 2004-04-30
JP2003523387A (ja) 2003-08-05

Similar Documents

Publication Publication Date Title
DE60119896D1 (de) Verwendung von pramipexol zur behandlung von tabak/nikotin abhängigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE275145T1 (de) Chinazolinderivate zur behandlung von tumoren
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
ATE358669T1 (de) Pyrazolderivate zur behandlung von hiv
ATE417606T1 (de) Phenethanolamin-derivate zur behandlung von erkrankungen der atemwege
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE538096T1 (de) Pyridinon-derivate zur behandlung von arteriosklerose
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60137929D1 (de) Verwendung von lanthan bei der behandlung von knochenerkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
DE60027209D1 (de) Arzneimittel enthaltend hydroxyapatite zur behandlung von knochengewebserkrankungen
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
ATE372118T1 (de) Die verwendung von rosiglitazon zur behandlung von psychiatrischen erkrankungen.
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60111520D1 (de) Hydroxyphenyl-piperazinyl-methyl-benzamid-derivate zur schmerzbehandlung
EE200200577A (et) Kinolinüülpiperidiin-4-ülideenmetüülbensamiidi derivaadid valu raviks
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
ATE314850T1 (de) Verwendung einer pharmazeutische zusammensetzung enthaltend desoxypeganin zur behandlung der nikotinabhängigkeit
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen

Legal Events

Date Code Title Description
8363 Opposition against the patent
8339 Ceased/non-payment of the annual fee
8331 Complete revocation
8380 Miscellaneous part iii

Free format text: DIE ZURUECKNAHME VOM 24.12.2008 WURDE GELOESCHT.